NAT2 and adenocarcinoma: For instance, there was an increased risk with homozygous NAT2*4 genotype, especially if gender, age and smoking factors are considered [9]; with homozygous c.341C+481T+803G and c.590A alleles [8]; with slow acetylator genotype in adenocarcinoma in patients < 65 years old [10]; or with slow acetylator in non-operable lung cancer, younger age, and lower smoking dose [14].